McGlinchey, Kelly

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Luo, F. R., Yang, Z., Camuso, A., Smykla, R., McGlinchey, K., Fager, K., Flefleh, C., Castaneda, S., Inigo, I., Kan, D., et al. (2006) · Clinical Cancer Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 151

Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer

Zanvit, P., van Dyk, D., Fazenbaker, C., McGlinchey, K., Luo, W., Pezold, J. M., Meekin, J., Chang, C.-Y., Carrasco, R. A., Breen, S., et al. (2023) · Journal of Clinical Investigation

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 60

GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory

Durham, N. M., Holoweckyj, N., MacGill, R. S., McGlinchey, K., Leow, C. C., & Robbins, S. H. (2017) · Journal for ImmunoTherapy of Cancer

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 48